Tocilizumab Effect on Lipid Profile in Correlation to Cardiovascular Events: A Retrospective Cohort Study.
Journal
International journal of rheumatology
ISSN: 1687-9260
Titre abrégé: Int J Rheumatol
Pays: United States
ID NLM: 101519204
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
01
2021
accepted:
18
07
2021
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
24
8
2021
Statut:
epublish
Résumé
To study the effect of tocilizumab initiation on the lipid profile, in correlation to a composite of any cardiovascular events. A retrospective cohort study, using data from the King Faisal Specialist Hospital & Research Centre database, from January 2014 to December 2019. Patients with rheumatoid arthritis or juvenile idiopathic arthritis who were ≥18 years old, initiated either on tocilizumab or other biologic treatment (anti-TNFs or Rituximab), were included, with a follow-up interval duration at a minimum of 6-12 months up to 3-5 years. Any patient with established cardiovascular disease or aged <18 were excluded. Only one cardiovascular mortality was reported in the tocilizumab group. Fifty percent of patients reached high cholesterol levels ≥ 5.2 mmol/L and LDL ≥ 3.37 mmol/L in the tocilizumab group at 36 months in a shorter time period compared to controls (60 months), There was a lack of evidence of increased cardiovascular risk in correlation to hyperlipidemia secondary to tocilizumab treatment.
Identifiants
pubmed: 34422057
doi: 10.1155/2021/5535486
pmc: PMC8378990
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5535486Informations de copyright
Copyright © 2021 Toka Alsulaim et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Int J Mol Sci. 2019 Sep 18;20(18):
pubmed: 31540528
Arthritis Res Ther. 2011;13(5):R141
pubmed: 21884601
Ann Pharmacother. 2008 Nov;42(11):1660-8
pubmed: 18957621
Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:27-42
pubmed: 22438671
Int J Rheumatol. 2015;2015:975028
pubmed: 26089907
PLoS One. 2019 Aug 1;14(8):e0220178
pubmed: 31369575
Am Heart J. 2013 Oct;166(4):622-628.e1
pubmed: 24093840
Arthritis Rheumatol. 2020 Jan;72(1):31-40
pubmed: 31469238
Mediators Inflamm. 2018 Oct 14;2018:2453265
pubmed: 30405318
Ann Rheum Dis. 2016 Oct;75(10):1806-12
pubmed: 26613768
J Rheumatol. 2011 Jan;38(1):10-20
pubmed: 20952462
Rev Recent Clin Trials. 2006 Sep;1(3):193-200
pubmed: 18473972
Ther Adv Musculoskelet Dis. 2018 Oct 07;10(10):195-199
pubmed: 30327685
Rheumatol Int. 2011 Apr;31(4):451-6
pubmed: 20024554
Ann Rheum Dis. 2010 Jan;69(1):88-96
pubmed: 19297346
Biologics. 2016 Mar 22;10:59-66
pubmed: 27069354
Arthritis Rheumatol. 2017 Jun;69(6):1154-1164
pubmed: 28245350